The global neurodegenerative disease treatment market size reached US$ 74.7 Billion in 2023. Looking forward, the publisher expects the market to reach US$ 114.6 Billion by 2032, exhibiting a growth rate (CAGR) of 4.87% during 2023-2032.
Neurodegenerative diseases refer to a group of brain disorders that lead to progressive degeneration of the structure and function of neurons in the central nervous system (CNS) or peripheral nervous system (PNS). Presently, several medications are available to reduce physical or mental symptoms and improve the quality of patients' life. Moreover, researchers are focusing on developing molecular diagnostics, especially biomarkers and imaging spectroscopy, to detect and diagnose neurodegenerative diseases at an early stage and prevent their progression.
The growing prevalence of tumors and stroke on account of excessive alcohol consumption, in confluence with the rising geriatric population, represents one of the major factors increasing the risk of developing neurodegenerative diseases. This is further escalating the need for molecular diagnostic techniques for early diagnosis of neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, Huntington's disease and amyotrophic lateral sclerosis. Apart from this, researchers are combining neuropathological methods with molecular biology techniques to understand the classification of these diseases effectively.
They are also developing minimally invasive (MI) screening tests for different types of neurodegenerative diseases. Furthermore, governing agencies of numerous countries, along with non-governmental organizations (NGOs), are supporting various health education campaigns to generate awareness about the risk factors of neurodegenerative diseases. Other factors, such as increasing access to healthcare facilities on account of improving infrastructure and inflating disposable incomes, are anticipated to drive the growth of the market in the coming years.
Neurodegenerative diseases refer to a group of brain disorders that lead to progressive degeneration of the structure and function of neurons in the central nervous system (CNS) or peripheral nervous system (PNS). Presently, several medications are available to reduce physical or mental symptoms and improve the quality of patients' life. Moreover, researchers are focusing on developing molecular diagnostics, especially biomarkers and imaging spectroscopy, to detect and diagnose neurodegenerative diseases at an early stage and prevent their progression.
The growing prevalence of tumors and stroke on account of excessive alcohol consumption, in confluence with the rising geriatric population, represents one of the major factors increasing the risk of developing neurodegenerative diseases. This is further escalating the need for molecular diagnostic techniques for early diagnosis of neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, Huntington's disease and amyotrophic lateral sclerosis. Apart from this, researchers are combining neuropathological methods with molecular biology techniques to understand the classification of these diseases effectively.
They are also developing minimally invasive (MI) screening tests for different types of neurodegenerative diseases. Furthermore, governing agencies of numerous countries, along with non-governmental organizations (NGOs), are supporting various health education campaigns to generate awareness about the risk factors of neurodegenerative diseases. Other factors, such as increasing access to healthcare facilities on account of improving infrastructure and inflating disposable incomes, are anticipated to drive the growth of the market in the coming years.
Key Market Segmentation:
The publisher provides an analysis of the key trends in each sub-segment of the global neurodegenerative disease treatment market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on indication, drug type, route of administration and distribution channel.Breakup by Indication:
- Multiple Sclerosis
- Parkinson’s Disease
- Alzheimer’s Disease
- Spinal Muscular Atrophy (SMA)
- Huntington’s Disease
- Others
Breakup by Drug Type:
- N-methyl-D-aspartate Receptor Antagonists
- Selective Serotonin Reuptake Inhibitors
- Dopamine Inhibitors
- Others
Breakup by Route of Administration:
- Oral
- Injectable
- Others
Breakup by Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Others
Breakup by Region:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Biogen, Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi S.A, Teva Pharmaceutical Industries Ltd. and UCB S.A.Key Questions Answered in This Report:
- How has the global neurodegenerative disease treatment market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global neurodegenerative disease treatment market?
- What are the key regional markets?
- What is the breakup of the market based on the indication?
- What is the breakup of the market based on the drug type?
- What is the breakup of the market based on the route of administration?
- What is the breakup of the market based on the distribution channel?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global neurodegenerative disease treatment market and who are the key players?
- What is the degree of competition in the industry?
Table of Contents
1 Preface3 Executive Summary12 Value Chain Analysis14 Price Analysis
2 Scope and Methodology
4 Introduction
5 Global Neurodegenerative Disease Treatment Market
6 Market Breakup by Indication
7 Market Breakup by Drug Type
8 Market Breakup by Route of Administration
9 Market Breakup by Distribution Channel
10 Market Breakup by Region
11 SWOT Analysis
13 Porters Five Forces Analysis
15 Competitive Landscape
List of Figures
List of Tables
Companies Mentioned
- Biogen
- Boehringer Ingelheim International GmbH
- F. Hoffmann-La Roche AG
- GlaxoSmithKline Plc
- Merck & Co. Inc.
- Novartis AG
- Pfizer Inc.
- Sanofi S.A
- Teva Pharmaceutical Industries Ltd.
- UCB S.A
Methodology
LOADING...
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 135 |
Published | August 2024 |
Forecast Period | 2023 - 2032 |
Estimated Market Value ( USD | $ 74.7 Billion |
Forecasted Market Value ( USD | $ 114.6 Billion |
Compound Annual Growth Rate | 4.9% |
Regions Covered | Global |
No. of Companies Mentioned | 10 |